Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma

Cancer Cell

Volumn 20, Issue 6, 2011, Pages 728-740

  Challa Malladi, Madhavi ^a   Lieu, Yen K ^a   Califano, Olivia ^a   Holmes, Antony B ^a   Bhagat, Govind ^a,b   Murty, Vundavalli V ^a,b   Dominguez Sola, David ^a   Pasqualucci, Laura ^a,b   Dalla Favera, Riccardo ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ANTIGEN RECOGNITION; ARTICLE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; LARGE CELL LYMPHOMA; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 83555173561     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.11.006     Document Type: Article

References (50)

1. Abramson J.S., Shipp M.A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005, 106:1164-1174.
2. Altomonte M., Gloghini A., Bertola G., Gasparollo A., Carbone A., Ferrone S., Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 1993, 53:3343-3348.
3. Billaud M., Rousset F., Calender A., Cordier M., Aubry J.P., Laisse V., Lenoir G.M. Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus. Blood 1990, 75:1827-1833.
4. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987, 329:506-512.
5. Bolhuis R.L., Roozemond R.C., van de Griend R.J. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J. Immunol. 1986, 136:3939-3944.
6. Boon T., van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 1996, 183:725-729.
7. Colonna M., Navarro F., Bellón T., Llano M., García P., Samaridis J., Angman L., Cella M., López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 1997, 186:1809-1818.
8. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
9. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
10. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
11. Dustin M.L., Selvaraj P., Mattaliano R.J., Springer T.A. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature 1987, 329:846-848.
12. Garrido F., Cabrera T., Aptsiauri N. " Hard" and " soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 2010, 127:249-256.
13. Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
14. Gwin J.L., Gercel-Taylor C., Taylor D.D., Eisenberg B. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells. J. Surg. Res. 1996, 60:129-136.
15. Hicklin D.J., Wang Z., Arienti F., Rivoltini L., Parmiani G., Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 1998, 101:2720-2729.
16. Huang J.Z., Sanger W.G., Greiner T.C., Staudt L.M., Weisenburger D.D., Pickering D.L., Lynch J.C., Armitage J.O., Warnke R.A., Alizadeh A.A., et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002, 99:2285-2290.
17. Hughes E.A., Hammond C., Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc. Natl. Acad. Sci. USA 1997, 94:1896-1901.
18. Iqbal J., Greiner T.C., Patel K., Dave B.J., Smith L., Ji J., Wright G., Sanger W.G., Pickering D.L., Jain S., et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007, 21:2332-2343. Leukemia/Lymphoma Molecular Profiling Project.
19. Jordanova E.S., Riemersma S.A., Philippo K., Schuuring E., Kluin P.M. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int. J. Cancer 2003, 103:393-398.
20. Kanner S.B., Damle N.K., Blake J., Aruffo A., Ledbetter J.A. CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling. J. Immunol. 1992, 148:2023-2029.
21. Kärre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319:675-678.
22. Klein U., Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 2008, 8:22-33.
23. Koopman L.A., Corver W.E., van der Slik A.R., Giphart M.J., Fleuren G.J. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 2000, 191:961-976.
24. Le P.T., Vollger L.W., Haynes B.F., Singer K.H. Ligand binding to the LFA-3 cell adhesion molecule induces IL-1 production by human thymic epithelial cells. J. Immunol. 1990, 144:4541-4547.
25. Lenz G., Staudt L.M. Aggressive lymphomas. N. Engl. J. Med. 2010, 362:1417-1429.
26. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
27. Mandelbaum J., Bhagat G., Tang H., Mo T., Brahmachary M., Shen Q., Chadburn A., Rajewsky K., Tarakhovsky A., Pasqualucci L., Dalla-Favera R. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010, 18:568-579.
28. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
29. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
30. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
31. Parham P., Barnstable C.J., Bodmer W.F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J. Immunol. 1979, 123:342-349.
32. Pasqualucci L., Migliazza A., Basso K., Houldsworth J., Chaganti R.S., Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003, 101:2914-2923.
33. Pasqualucci L., Compagno M., Houldsworth J., Monti S., Grunn A., Nandula S.V., Aster J.C., Murty V.V., Shipp M.A., Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 2006, 203:311-317.
34. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., Kasper L.H., Lerach S., Tang H., Ma J., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
35. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., Wells V.A., Grunn A., Messina M., Elliot O., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 2011, 43:830-837.
36. Peaper D.R., Cresswell P. Regulation of MHC class I assembly and peptide binding. Annu. Rev. Cell Dev. Biol. 2008, 24:343-368.
37. Riemersma S.A., Jordanova E.S., Schop R.F., Philippo K., Looijenga L.H., Schuuring E., Kluin P.M. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000, 96:3569-3577.
38. Rimsza L.M., Roberts R.A., Miller T.P., Unger J.M., LeBlanc M., Braziel R.M., Weisenberger D.D., Chan W.C., Muller-Hermelink H.K., Jaffe E.S., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004, 103:4251-4258.
39. Rosa F., Berissi H., Weissenbach J., Maroteaux L., Fellous M., Revel M. The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J. 1983, 2:239-243.
40. Sanchez-Madrid F., Krensky A.M., Ware C.F., Robbins E., Strominger J.L., Burakoff S.J., Springer T.A. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc. Natl. Acad. Sci. USA 1982, 79:7489-7493.
41. Springer T.A., Dustin M.L., Kishimoto T.K., Marlin S.D. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu. Rev. Immunol. 1987, 5:223-252.
42. Stam N.J., Vroom T.M., Peters P.J., Pastoors E.B., Ploegh H.L. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int. Immunol. 1990, 2:113-125.
43. Staudt L.M., Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol. 2005, 87:163-208.
44. Steidl C., Shah S.P., Woolcock B.W., Rui L., Kawahara M., Farinha P., Johnson N.A., Zhao Y., Telenius A., Neriah S.B., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-381.
45. Sunyaev S., Ramensky V., Koch I., Lathe W., Kondrashov A.S., Bork P. Prediction of deleterious human alleles. Hum. Mol. Genet. 2001, 10:591-597.
46. Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 2005, 115:433-440.
47. Townsend A.R., Gotch F.M., Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985, 42:457-467.
48. Wang J.H., Smolyar A., Tan K., Liu J.H., Kim M., Sun Z.Y., Wagner G., Reinherz E.L. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell 1999, 97:791-803.
49. Ye B.H., Lista F., Lo Coco F., Knowles D.M., Offit K., Chaganti R.S., Dalla-Favera R. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993, 262:747-750.
50. Zinkernagel R.M., Doherty P.C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974, 251:547-548.